CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 701–800 of 1,010
Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Norde, W. J., Hobo, W. A., van der Voort, R., & Dolstra, H. (2012) · Blood · doi:10.1182/blood-2012-02-412510 · Cited by 91
Ko, H.-J., Cho, M., Lee, S.-Y., Oh, H., Heo, Y., Moon, Y., Kang, C., Kwok, S., Ju, J. H., Park, S., et al. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.07.006 · Cited by 89
Liu, Q., Zheng, H., Chen, X., Peng, Y., Huang, W., Li, X., Li, G., Xia, W., Sun, Q., & Xiang, A. P. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.118 · Cited by 85
Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita, H., Gejyo, F., Okumura, K., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903033 · Cited by 82
“7), suggesting that effect of antagonistic anti– CTLA-4 mAb alone is possibly mediated by inhibition of CD4 regulatory T cell function, consistent with CTLA-4 reported as a critical effector molecule expressed on regulatory T cells (12).”
BackgroundSavoia, P., Astrua, C., & Fava, P. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1129478 · Cited by 90
“Moreover CTLA4 is constitutively highly expressed on FOXP3C regulatory T cells, playing a role in their suppressive functions.(17) In fact, when a T cell recognizes a tumor antigen, signaling through the CTLA-4 pathway prevents the co-stimulatory signal, leading to an inhibitory mechanism on the immune response.”
BackgroundLiu, S. Q., Sun, X., Luo, J., Zhu, H., Yang, X., Guo, Q., Song, Y., & Sun, X. (2015) · PubMed Central · Cited by 91
Dilek, N., Poirier, N., Hulin, P., Coulon, F., Mary, C., Ville, S., Vie, H., Clémenceau, B., Blancho, G., & Vanhove, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083139 · Cited by 74
“CTLA-4 itself is required for suppression by Tregs [21] in an intrinsic manner by promoting FoxP3 induction [22], and in an extrinsic manner by inducing IDO in dendritic cells [23] and capturing its CD80/86 ligands from APCs by a process of trans-endocytosis [24].”
BackgroundRelevance of Regulatory T Cells during Colorectal Cancer Development
Olguín, J. E., Medina-Andrade, I., Rodríguez, T., Rodríguez‐Sosa, M., & Terrazas, L. I. (2020) · Cancers · doi:10.3390/cancers12071888 · Cited by 89
Cyclic AMP underpins suppression by regulatory T cells
Bodor, J., Bopp, T., Vaeth, M., Klein, M., Serfling, E., Hünig, T., Becker, C., Schild, H., & Schmitt, E. (2012) · European Journal of Immunology · doi:10.1002/eji.201141578 · Cited by 90
Chen, X., & Oppenheim, J. J. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03460.x · Cited by 88
Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand
Maddur, M. S., Sharma, M., Hegde, P., Victor, E. S., Pulendran, B., Kaveri, S. V., & Bayry, J. (2014) · Nature Communications · doi:10.1038/ncomms5092 · Cited by 88
Molecular orchestration of differentiation and function of regulatory T cells
Lu, L.-F., & Rudensky, A. (2009) · Genes & Development · doi:10.1101/gad.1791009 · Cited by 78
“Long-lasting Treg cell interactions with DCs were convincingly documented by recent studies employing intravital microscopy (Tadokoro et al. 2006; Tang et al. 2006).”
BackgroundInfluentialClinical Development of Immune Checkpoint Inhibitors
Ito, A., Kondo, S., Tada, K., & Kitano, S. (2015) · BioMed Research International · doi:10.1155/2015/605478 · Cited by 87
“If they contact antigens without costimulatory ligands on antigen presenting cells (APCs), T cells remain inactivated in a state of anergy.”
BackgroundIL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors
DeLong, J. H., Hall, A. O., Rausch, M., Moodley, D., Perry, J. A., Park, J., Phan, A. T., Beiting, D. P., Kedl, R. M., Hill, J. A., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1800083 · Cited by 86
CTLA-4 (CD152): A versatile receptor for immune-based therapy
Lingel, H., & Brunner-Weinzierl, M. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101298 · Cited by 80
Magee, C. N., Boenisch, O., & Najafian, N. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04180.x · Cited by 86
“Th1 Cellular immunity against intracellular pathogens Hypersensitivity CD40L (18) TIM-3 (47,50–52) Viral immunity Autoimmunity TIM-1 (33) CTLA-4 (41) CD28 (10) PDL-1 (59) OX40 (61) ICOS (76,77) Th2 Humoral immunity Allergy CD28 (10,65,66) CTLA-4 (41) B cell help—regulate B cell activation and antibody class switching…”
BackgroundFelonato, M., Pina, A., de Araújo, E. F., Loures, F. V., Bazan, S. B., Feriotti, C., & Calich, V. L. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051071 · Cited by 86
Bae, M., Shin, H. S., See, H.-J., Jung, S. Y., Kwon, D., & Shon, D. (2016) · Scientific Reports · doi:10.1038/srep32225 · Cited by 86
Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation
Togashi, Y., & Nishikawa, H. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_58 · Cited by 86
“In mice, Treg-specific deletion of CTLA-4 elicits systemic hyper-proliferation of Tconvs, resulting in fatal autoimmune diseases affecting multiple organs, including severe myocarditis (Wing et al. 2008).”
BackgroundInfluentialReview of immune checkpoint inhibitors in immuno-oncology
Jacob, J. B., Jacob, M. K., & Parajuli, P. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.01.002 · Cited by 86
The role of regulatory T cells in neurodegenerative diseases
HeFeng, F. Q., & Balling, R. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1187 · Cited by 79
Cellular response to mycobacteria: balancing protection and pathology
Torrado, E., Robinson, R., & Cooper, A. M. (2011) · Trends in Immunology · doi:10.1016/j.it.2010.12.001 · Cited by 85
PKC-θ function at the immunological synapse: prospects for therapeutic targeting
Zanin‐Zhorov, A., Dustin, M. L., & Blazar, B. R. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.007 · Cited by 87
Lessons from CTLA-4 deficiency and checkpoint inhibition
Lo, B., & Abdel‐Motal, U. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.014 · Cited by 86
Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry
Shibru, B., Fey, K., Fricke, S., Blaudszun, A., Fürst, F., Weise, M., Seiffert, S., Weyh, M. K., Koehl, U., Sack, U., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694055 · Cited by 85
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Archilla‐Ortega, A., Domuro, C., Martín-Liberal, J., & Muñoz, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02264-x · Cited by 84
The Evolution, Immunopathogenesis and Biomarkers of Type 2 Inflammation in Common Allergic Disorders
Gao, Y., Wang, Z., Öğülür, İ., Li, S., Yazıcı, D., Li, X., Pat, Y., Zheng, Y., Babayev, H., Zeyneloglu, C., et al. (2025) · Allergy · doi:10.1111/all.16620 · Cited by 84
Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells
Maddur, M. S., Othy, S., Hegde, P., Vani, J., Lacroix‐Desmazes, S., Bayry, J., & Kaveri, S. V. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9394-5 · Cited by 84
“Treg interaction with DCs mediated by CTLA-4, LAG3, and suppressor cytokines has been shown to downregulate the expression of co-stimulatory molecules CD80 (B7-1), CD86 (B7-2), and CD40 and the MHC–peptide complexes while upregulating the inhibitory B7-H3 molecules that lead to an impaired T cell stimulatory function…”
BackgroundBar‐On, L., Birnberg, T., Kim, K.-W., & Jung, S. (2010) · European Journal of Immunology · doi:10.1002/eji.201041169 · Cited by 84
Homeostasis and function of regulatory T cells (Tregs) in vivo : lessons from TCR ‐transgenic Tregs
Attridge, K., & Walker, L. S. K. (2014) · Immunological Reviews · doi:10.1111/imr.12165 · Cited by 84
“The importance of CTLA-4 expression for Treg suppression of diabetes was consistent with the immune dysregulation triggered by Treg-specific deletion of the ctla-4 gene (117) and has since been confirmed in another diabetes system where disease is driven by T cells responding to an endogenous pancreatic self-antigen (…”
BackgroundResultTkachev, V., Furlan, S. N., Watkins, B. K., Hunt, D. J., Zheng, H. B., Panoskaltsis‐Mortari, A., Betz, K., Brown, M., Schell, J. B., Zeleski, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3085 · Cited by 84
Immunotherapy for cancer in the central nervous system: Current and future directions
Binder, D. C., Davis, A. A., & Wainwright, D. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1082027 · Cited by 83
“CTLA-4 is also expressed on CD4C T cells where it functions to enhance Treg-mediated immunosuppression.(47) Ipilimumab, a humanized CTLA-4 antibody, was”
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 84
New Insights into the Role of the Immune Microenvironment in Breast Carcinoma
de la Cruz‐Merino, L., Barco-Sánchez, A., Henao, F., Fernández, E. N., Benítez, A. V., Molina, J. B., Martínez-Peinado, A., López, A. G., Borrego, M. R., de Villena, M. C. M., et al. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/785317 · Cited by 85
“In preclinical studies with knockout mice it has been reported that CTLA-4 deficiency in CD4+CD25+ Treg impairs its suppressive function in tumor immunity [61, 62].”
BackgroundPoirier, N., Mary, C., Dilek, N., Hervouet, J., Minault, D., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04164.x · Cited by 83
“CTLA-4 is also required for the function of regulatory T cells (Tregs) (1), which suppress aberrant immune responses and are important for inducing tolerance toward transplanted tissue (2).”
BackgroundGenetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 84
“In contrast to the broad expression of PD-1, cytotoxic T lymphocyte antigen-4 (CTLA-4) is mainly expressedonTreg cellsandcontrols immunologicalself-toleranceandTreg-inducedimmunosuppression[57,58].”
BackgroundRedox remodeling as an immunoregulatory strategy
Yan, Z., & Banerjee, R. (2010) · Biochemistry · doi:10.1021/bi902022n · Cited by 82
Regulatory T-Cell Therapy in the Induction of Transplant Tolerance: The Issue of Subpopulations
Edozie, F. C., Nova‐Lamperti, E., Povoleri, G. A. M., Scottà, C., John, S., Lombardi, G., & Afzali, B. (2014) · Transplantation · doi:10.1097/tp.0000000000000243 · Cited by 83
“In this context, CTLA-4 is a classic example with unequivocal evidence from wild type and CTLA-4 knock-out mice showing its critical function in Tregs (67, 69).”
BackgroundExhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment
McRitchie, B., & Akkaya, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940052 · Cited by 83
“Nat Rev Mol Cell Biol (2018) 19(7):419–35.”
Regulatory T cells and immune tolerance to tumors
Cao, X. (2009) · Immunologic Research · doi:10.1007/s12026-009-8124-7 · Cited by 84
“This work provides convincing evidence to support the notion that CTLA-4 is an effector molecule that is essential for Treg-mediated self-tolerance as well as tumor tolerance [79].”
BackgroundThe role of regulatory T cells in IgE-mediated food allergy.
Palomares, Ó. (2013) · PubMed · Cited by 85
T-Regulatory Cells In Tumor Progression And Therapy
Verma, A., Mathur, R., Farooque, A., Kaul, V., Gupta, S., & Dwarakanath, B. S. R. (2019) · Cancer Management and Research · doi:10.2147/cmar.s228887 · Cited by 81
“CTLA-4 deficiency results in lymphoproliferation followed by splenomegaly, development of autoimmune diseases and increased IgE secretion in Treg-specific Foxp3 CTLA-4 deficient mice, similar to Foxp3 deficient mice.(33) Thus, inhibition of CTLA-4 has been found to increase the immune response against pre-established…”
BackgroundAdverse events induced by immune checkpoint inhibitors
Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 83
“Finally, CTLA-4 on Tregs is an important modulator of Treg function [46].”
BackgroundDiagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers, B., Leaf, D. E., Porta, C., Soler, M. J., & Perazella, M. A. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00630-8 · Cited by 81
Zhang, W., Tan, Y., Li, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1234142 · Cited by 82
“In addition, some tumors prompt regulatory T cells (Tregs) to express CTLA-4, leading to downregulation of CD80/CD86 expression in antigen-presenting cells, resulting in reduced production of cytokines such as interleukin 2, which affects the body’s anti-tumor capacity (66).”
BackgroundThe functional and prognostic implications of regulatory T cells in colorectal carcinoma.
Zhang, X., Kelaria, S., Kerstetter, J. C., & Wang, J. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.017 · Cited by 81
“For example, CTLA-4 is critical in activity of Tregs (10).”
BackgroundBreaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression
Mercadante, E. R., & Lorenz, U. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00193 · Cited by 71
“Furthermore, genetic models where key components of Treg function are impaired, such as CTLA-4 KO (10) or IL-10 KO (11) mice, supported the idea that Tregs were necessary for immune tolerance, and were the likely culprits in autoimmune disease.”
BackgroundRegulatory T cells in kidney disease and transplantation
Hu, M., Wang, Y. M., Wang, Y., Zhang, G. Y., Zheng, G., Yi, S., O’Connell, P. J., Harris, D. C. H., & Alexander, S. I. (2016) · Kidney International · doi:10.1016/j.kint.2016.03.022 · Cited by 82
Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells
Bourque, J., & Hawiger, D. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026790 · Cited by 82
The panoply of αβT cells in the skin
Nomura, T., Kabashima, K., & Miyachi, Y. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.07.010 · Cited by 68
Self-citationSynergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
Oladejo, M., Paulishak, W., & Wood, L. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.003 · Cited by 80
Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns
Gougis, P., Hamy, A., Jochum, F., Bihan, K., Carbonnel, M., Salem, J., Dumas, É., Kabirian, R., Grandal, B., Barraud, S., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5625 · Cited by 80
Emerging roles of regulatory T cells in tumour progression and metastasis
Halvorsen, E. C., Mahmoud, S., & Bennewith, K. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9529-x · Cited by 81
Identification of heme oxygenase-1–specific regulatory CD8+ T cells in cancer patients
Andersen, M. H., Sørensen, R. B., Brimnes, M. K., Svane, I. M., Becker, J. C., & Straten, P. T. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38739 · Cited by 81
CTLA-4 blockade and the renaissance of cancer immunotherapy
Mocellin, S., & Nitti, D. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.05.003 · Cited by 80
CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells
Solstad, T., Bains, S. J., Landskron, J., Aandahl, E. M., Thiede, B., Taskén, K., & Torgersen, K. M. (2011) · Blood · doi:10.1182/blood-2011-02-339242 · Cited by 72
Suppression of Th2 and Tfh immune reactions by Nr4a receptors in mature T reg cells
Sekiya, T., Kondo, T., Shichita, T., Morita, R., Ichinose, H., & Yoshimura, A. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142088 · Cited by 72
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 80
“Tregs are potent inhibitors of CD8+ T-cells as they compete for IL-2 (201), generate adenosine by CD39/CD73 (202), and via CTLA-4 downregulate CD80/ CD86 on DCs that are needed by T-cells for costimulation (203) while upregulating indoleamine 2,3-dioxygenase-1 (IDO-1) in DCs (204, 205).”
BackgroundHaas, O. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03136 · Cited by 81
“The encoded transcription factor controls the function of regulatory T cells that are essential for maintaining self-tolerance and immune homeostasis by suppressing aberrant responses such as autoimmunity and allergy (166).”
BackgroundImmunotherapy for prostate cancer: recent developments and future challenges
Schweizer, M. T., & Drake, C. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9479-8 · Cited by 80
“For one, it has been found that CTLA-4 is critical to Treg function, with mice harboring CTLA-4 deficient Tregs developing fatal T-cell-mediated autoimmune disease [22].”
BackgroundImmunotherapeutic strategies for relapse control in acute myeloid leukemia
Martner, A., Thorén, F. B., Aurelius, J., & Hellstrand, K. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.006 · Cited by 79
“Thus, Tregs down-modulate CD80 and CD86 by DCs in a CTLA-4 dependent manner, rendering the DCs less capable of initiating immune responses [79,80].”
BackgroundInfluentialCancer/testis antigens: from serology to mRNA cancer vaccine
Fan, C., Qu, H., Wang, X., Sobhani, N., Wang, L., Liu, S., Xiong, W., Zeng, Z., & Li, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.016 · Cited by 79
Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease
Liberal, R., Grant, C. R., Longhi, M. S., Mieli‐Vergani, G., & Vergani, D. (2015) · IUBMB Life · doi:10.1002/iub.1349 · Cited by 79
“The importance of CTLA-4 for Treg function has been shown by the use of CTLA-4 specific blocking antibodies (65) and Treg-specific Ctla-4 knock-out mice (66): in the absence of functional CTLA-4, Treg-mediated suppression of effector T cells was reduced, with consequent autoimmune disease.”
Re-establishing immunological self-tolerance in autoimmune disease
Sakaguchi, S., Powrie, F. M., & Ransohoff, R. M. (2012) · Nature Medicine · doi:10.1038/nm.2622 · Cited by 81
Self-citationDynamic Behavior and Function of Foxp3+ Regulatory T Cells in Tumor Bearing Host
Qin, F. X.-F. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.2 · Cited by 79
Sun, L., Jin, H., & Li, H. (2016) · Oncotarget · doi:10.18632/oncotarget.8753 · Cited by 82
“Thus, the use of CD25 as a surface marker of Tregs seems to be unconvinced, considering that human CD4+CD25+ T cells Review Oncotarget42827www.impactjournals.com/oncotarget table 1: tregs markers Marker comment referenceSurface H igh CD25 Only 1~2% of CD4 + T cells with highest CD25 expression are Tregs with suppressi…”
BackgroundInfluentialCheckpoint immunotherapy by nivolumab for treatment of metastatic melanoma
Koppolu, V., & Vasigala, V. R. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1290_16 · Cited by 79
Regulatory T Cells As Potential Targets for HIV Cure Research
Kleinman, A. J., Sivanandham, R., Pandrea, I., Chougnet, C. A., & Apetrei, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00734 · Cited by 80
“A similar fatal autoimmune disease occurs if CTLA-4 is deleted from Tregs using Cre/lox with the FoxP3 promoter, due to loss of Treg suppressive function, particularly, lack of Treg-mediated DC CD80 and CD86 expression (14).”
BackgroundHoeppli, R. E., MacDonald, K. N., Leclair, P., Fung, V. C. W., Mojibian, M., Gillies, J., Rahavi, S. M. R., Campbell, A. I. M., Gandhi, S. K., Pesenacker, A. M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.14936 · Cited by 74
CD4 T Cells Reactive to Hybrid Insulin Peptides Are Indicators of Disease Activity in the NOD Mouse
Baker, R. L., Jamison, B. L., Wiles, T. A., Lindsay, R. S., Barbour, G., Bradley, B., Delong, T., Friedman, R. S., Nakayama, M., & HASKINS, K. M. (2018) · Diabetes · doi:10.2337/db18-0200 · Cited by 79
Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease
Horst, A. K., Kumashie, K. G., Neumann, K., Diehl, L., & Tiegs, G. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00568-6 · Cited by 70
Identification and Clinical Relevance of Naturally Occurring Human CD8+HLA-DR+ Regulatory T Cells
Arruvito, L., Payaslián, F., Baz, P., Podhorzer, A., Billordo, L. A., Pandolfi, J. B., Semeniuk, G. B., Arribalzaga, E. B., & Fainboim, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401490 · Cited by 78
Red blood cells as innovative antigen carrier to induce specific immune tolerance
Cremel, M., Guérin, N., Horand, F., Banz, A., & Godfrin, Y. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.12.044 · Cited by 78
Kornete, M., & Piccirillo, C. A. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00165 · Cited by 78
“Treg cells constitutively express high levels of CTLA-4 and conditional deficiency of CTLA-4 in Treg cells results in lymphoproliferation and variety of autoimmune disease, an outcome analogous to global CTLA-4 deficient mice (Wing et al., 2008).”
ResultIn vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis
Moon, S., Park, J., Heo, Y., Kang, C., Kim, E., Lim, M., Ryu, J., Park, S. J., Park, K. S., Sung, Y., et al. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.89 · Cited by 78
Requirement of full TCR repertoire for regulatory T cells to maintain intestinal homeostasis
Nishio, J., Baba, M., Atarashi, K., Tanoue, T., Negishi, H., Yanai, H., Habu, S., Hori, S., Honda, K., & Taniguchi, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516617112 · Cited by 78
“In this regard, the coinhibitory molecule CTLA-4 expressed by Tregs interacts with CD80 and CD86 on DCs via transendocytosis, leading to down-regulation of expression of these molecules in vitro (16, 17).”
BackgroundSundström, P., Stenstad, H., Langenes, V., Ahlmanner, F., Theander, L., Ndah, T. G., Fredin, K., Börjesson, L., Gustavsson, B. G., Bastid, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0050 · Cited by 79
“For example, our observation of increased expression of CTLA-4 in CD39þ Tregs suggests that they may also potently reduce antitumor immune effector functions in an adenosine-independent manner (7).”
BackgroundReverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 78
“LAG-3 is expressed in activated CD4+ and CD8+ T cells 3–4 days post activation (127), on a subset of NK cells (128) and on activated Tregs (129).”
BackgroundInfluentialCharbonnier, L., Vokaer, B., Lemaitre, P. H., Field, K. A., Léo, O., & Moine, A. L. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04184.x · Cited by 77
“Although a specific deficiency of CTLA4 in Foxp3+ CD4+ T cells dramatically enhances the number of peripheral Tregs (32), CTLA4-Ig administration (by”
BackgroundSvensson, H., Olofsson, V., Lundin, S. B., Yakkala, C., Björck, S., Börjesson, L., Gustavsson, B. G., & Quiding‐Järbrink, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030695 · Cited by 77
“We could, however, extend the previous findings by a more detailed characterization of tumor associated Tregs.”
BackgroundInfluentialZhuo, C., Xu, Y., Ying, M., Li, Q., Huang, L., Li, D., Cai, S., & Li, B. (2015) · Immunologic Research · doi:10.1007/s12026-014-8616-y · Cited by 77
“In addition, the interpretation of the results obtained using these methods can be ambiguous and subjective [4, 19, 69, 104].”
BackgroundFrom immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 78
Rudqvist, N.-P., Charpentier, M., Lhuillier, C., Wennerberg, E., Spada, S., Sheridan, C. K., Zhou, X. K., Zhang, T., Formenti, S. C., Sims, J. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40844-3 · Cited by 76
“…T cell activation by hindering CD28-mediated signaling on conventional and regulatory T cells 10 – 12 , by enhancing T cellmotility 13 ,andbyreducingco-stimulatorymoleculesexpressionon antigen-presenting cells, an effect mediated by regulatory T cells (Treg) that express high CTLA4 levels 14,15 .”
Bolton, H. A., Zhu, E., Terry, A. M., Guy, T. V., Koh, W., Tan, S., Power, C. A., Bertolino, P., Lahl, K., Sparwasser, T. D., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76031 · Cited by 76
“Treg-dependent downregulation of CD80/CD86 expression in vitro requires CTLA-4 (28, 29).”
BackgroundLiu, X., Gao, N., Li, M., Xu, D., Hou, Y., Wang, Q., Zhang, G., Sun, Q., Zhang, H., & Zeng, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064531 · Cited by 76
“CLTA-4 is a protein receptor predominantly found on T lymphocytes and plays an important role in Treg function [19].”
BackgroundBarzaghi, F., Passerini, L., Gambineri, E., Mannurita, S. C., Cornu, T. I., Kang, E., Choe, Y. H., Cancrini, C., Corrente, S., Ciccocioppo, R., et al. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.12.009 · Cited by 76
Plesca, I., Tunger, A., Müller, L., Wehner, R., Lai, X., Grimm, M., Rutella, S., Bachmann, M. P., & Schmitz, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00364 · Cited by 76
“CTLA-4 is constitutively expressed on regulatory T (Treg) cells, enhancing their immunosuppressive activity (24).”
BackgroundFoxp3+ Regulatory T Cells in Tuberculosis
Larson, R. P., Shafiani, S., & Urdahl, K. B. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6111-1_9 · Cited by 81
REVIEW ARTICLE: B7 Family Molecules as Regulators of the Maternal Immune System in Pregnancy
Petroff, M. G., & Perchellet, A. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00841.x · Cited by 75
Lahl, K., Mayer, C. T., Bopp, T., Huehn, J., Loddenkemper, C., Eberl, G., Wirnsberger, G., Dornmair, K., Geffers, R., Schmitt, E., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803762 · Cited by 75
Bianco, B., André, G. M., Vilarino, F. L., Peluso, C., Mafra, F. A., Christofolini, D. M., & Barbosa, C. P. (2012) · Human Immunology · doi:10.1016/j.humimm.2011.12.009 · Cited by 72
“(2008) [89] showed that a specific deficiency of CTLA4 in Tregs resulted in spontaneous development of systemic lymphoproliferation, fatal T-cell–mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice.”
BackgroundInfluentialZhang, Q., Leong, S. C., McNamara, P. S., Mubarak, A., Malley, R., & Finn, A. H. R. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002175 · Cited by 75
“Some phenotypic markers such as CD39 and CTLA-4 have been found to be associated with the activity of Treg [6–9].”
Animal Models of Autoimmune Neuropathy
Soliven, B. C. (2014) · ILAR Journal · doi:10.1093/ilar/ilt054 · Cited by 76
“In contrast, both receptors are required for optimal generation and function of CD4+ Tregs (Salomon et al. 2000; Wing et al. 2008).”
BackgroundHIV persistence in subsets of CD4+ T cells: 50 shades of reservoirs
Fromentin, R., & Chomont, N. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101438 · Cited by 78
Immune profiles in primary squamous cell carcinoma of the head and neck
Saloura, V., Izumchenko, E., Zuo, Z., Bao, R., Korzinkin, M., Ozerov, I. V., Zhavoronkov, A. A., Sidransky, D., Bedi, A., Hoque, M. O., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.032 · Cited by 74
“Notably, the increase in exhausted CD8+ T-cells in TCIP-H patients, as demonstrated by the deconvolution analysis, suggests that elevation of these key immune checkpoints creates a dysfunctional tumor immune microenvironment which hinders CD8+ T-cell cytotoxicity and function [19, 20, 29, 30].”
BackgroundImmune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view
Memon, H., & Patel, B. M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116713 · Cited by 74
Fc Receptor-Like 3 Protein Expressed on IL-2 Nonresponsive Subset of Human Regulatory T Cells
Nagata, S., Ise, T., & Pastan, I. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802230 · Cited by 74
“Although an exclusive surface marker for nTreg cells has not yet been identified, CTLA-4 and glucocorticoid-induced TNF receptor family-related protein (GITR) are suggested by their involvement in Treg cell suppressive activity (16, 17).”
BackgroundWirsdörfer, F., Cappuccini, F., Niazman, M., de Leve, S., Westendorf, A. M., Lüdemann, L., Stuschke, M., & Jendrossek, V. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-98 · Cited by 74
“Abbreviations APC: Antigen presenting cell; BALF: Bronchoalveolar lavage fluid; CD39: Ectoapyrase; CD73: 5′Ectonucleotidase; CFSE: Carboxyfluorescein succinimidyl ester; cLN: Cervical lymph node; CTLA-4: Cytotoxic T-Lymphocyte Antigen 4; FoxP3: Forkhead box protein 3; Gy: Gray; IL: Interleukin; IMRT: Intensitymodulate…”
InfluentialRegulation of antigen‐expressing dendritic cells by double negative regulatory T cells
Gao, J. F., McIntyre, M. S. F., Juvet, S., Diao, J., Li, X., Vanama, R., Mak, T. W., Cattral, M. S., & Zhang, L. (2011) · European Journal of Immunology · doi:10.1002/eji.201141428 · Cited by 74
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
Schneider, H., & Rudd, C. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00619 · Cited by 75
“Trans-endocytosis or the removal of CD80 or CD86 from the surface of DCs may also occur (83, 84).”
BackgroundInfluential
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.